When multiple potential partners say yeah nah, not interested., page-19

‘But the trial is still going.This means patients are showing real benefits from our cancer drug.‘
~ @antibotter

Yawn. Just another meaningless assumption and feel good statement from a supposed significant shareholder trying to get the share price up.

The forum heard you say that the same thing about the DEP-Docetaxel trial for 5 long years after it was supposed to finish way back in 2018.

IMO the l long-overdue 2023 results ended up being completely underwhelming and the chance of Starpharma’s once flagship DEP drug getting licenced is now next to zero.

Keep pumping though.